MCID: DBT009
MIFTS: 66

Diabetes Mellitus

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Diabetes Mellitus

MalaCards integrated aliases for Diabetes Mellitus:

Name: Diabetes Mellitus 12 75 29 55 6 44 15 17 72 33
Diabetes 43 3 15 40 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9351
ICD9CM 35 250
MeSH 44 D003920
NCIt 50 C2985
SNOMED-CT 68 73211009
UMLS 72 C0011847 C0011849

Summaries for Diabetes Mellitus

MedlinePlus : 43 Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes. Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes. Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, also known as diabetes, is related to diabetes mellitus, permanent neonatal and neonatal diabetes mellitus, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus is KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11), and among its related pathways/superpathways are MicroRNAs in cancer and Type II diabetes mellitus. The drugs Ramipril and Nicorandil have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes.

Disease Ontology : 12 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

CDC : 3 Diabetes is a chronic (long-lasting) disease that affects how your body turns food into energy. There are three main types of diabetes: type 1, type 2, and gestational diabetes (diabetes while pregnant).

Novus Biologicals : 56 Diabetes is a disease in which the body does not produce or properly use insulin. There are four major types of diabetes: Type 1, Type 2, Gestational and Pre-Diabetes. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disease resulting when one's own immune system destroys insulin-producing beta cells in the pancreas. This causes the pancreas to produce little or no insulin. In type 2 diabetes, the body either does not produce enough insulin or beta cells ignore insulin. Gestational diabetes refers to high glucose levels caused by pregnancy. Pre-diabetes is a condition in which blood glucose levels are high, but not high enough for the diagnosis of type 2 diabetes.

Wikipedia : 75 Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by... more...

Related Diseases for Diabetes Mellitus

Diseases in the Diabetes Mellitus family:

Diabetes Mellitus, Congenital Autoimmune Type 1 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 3 Type 1 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 5 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 11
Type 1 Diabetes Mellitus 12 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 17
Type 1 Diabetes Mellitus 18 Rare Diabetes Mellitus Type 1
Rare Diabetes Mellitus Type 2 Rare Diabetes Mellitus

Diseases related to Diabetes Mellitus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3573)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, permanent neonatal 36.5 KCNJ11 INS ABCC8
2 neonatal diabetes mellitus 36.2 KCNJ11 INS ABCC8
3 diabetes mellitus, transient neonatal, 1 36.1 KCNJ11 INS ABCC8
4 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 35.8 KCNJ11 ABCC8
5 thiamine-responsive megaloblastic anemia syndrome 35.5 KCNJ11 INS ABCC8
6 insulinomatosis and diabetes mellitus 35.5 INS ABCC8
7 diabetes mellitus, noninsulin-dependent 35.4 PVT1 KCNJ11 INS CDKN2B-AS1 ABCC8
8 maturity-onset diabetes of the young, type 10 35.0 KCNJ11 INS
9 maturity-onset diabetes of the young, type 1 34.9 KCNJ11 INS ABCC8
10 pancreatic agenesis 34.2 KCNJ11 INS ABCC8
11 hypoglycemia 34.1 KCNJ11 INS ABCC8
12 hyperglycemia 33.5 MALAT1 KCNJ11 INS ABCC8
13 microvascular complications of diabetes 3 33.5 PVT1 MALAT1 INS
14 hyperinsulinism 33.3 KCNJ11 INS ABCC8
15 abdominal obesity-metabolic syndrome 1 33.0 MEG3 INS
16 acute insulin response 32.8 KCNJ11 INS ABCC8
17 monogenic diabetes 32.6 KCNJ11 INS ABCC8
18 insulinoma 32.5 MEN1 INS ABCC8
19 pancreas disease 32.5 KCNJ11 INS ABCC8
20 glucose metabolism disease 32.3 KCNJ11 INS ABCC8
21 hyperinsulinemic hypoglycemia 32.1 MEN1 KCNJ11 INS ABCC8
22 coronary heart disease 1 32.0 MIR17 MIR155 MIR145 INS CDKN2B-AS1
23 hypertension, essential 31.9 MIR155 MEN1 INS CDKN2B-AS1
24 atherosclerosis susceptibility 31.9 TUG1 INS CDKN2B-AS1
25 prostate disease 31.7 MEG3 MALAT1 CDKN2B-AS1
26 hirata disease 31.5 INS ABCC8
27 maturity-onset diabetes of the young, type 13 31.5 KCNJ11 INS ABCC8
28 munchausen by proxy 31.3 KCNJ11 ABCC8
29 fanconi-bickel syndrome 31.3 INS ABCC8
30 polymyositis 30.9 MIR155 MIR132
31 dermatomyositis 30.8 MIR155 MIR132
32 lymphoma, hodgkin, classic 30.6 PVT1 MIR155 MIR140
33 ovarian epithelial cancer 30.5 MEG3 MALAT1
34 pituitary adenoma 30.4 MIR197 MIR132 MEG3 MALAT1
35 endometriosis 30.4 MIR99A MIR145 CDKN2B-AS1
36 pancreatic endocrine carcinoma 30.4 MEG3 INS
37 diffuse large b-cell lymphoma 30.3 MIR99A MIR155 MIR145
38 pancreatic ductal adenocarcinoma 30.1 PVT1 MIR375 MIR155 MIR145 MALAT1
39 kidney cancer 30.1 PVT1 MIR17 MEG3 MALAT1
40 thyroid cancer, nonmedullary, 1 29.7 PVT1 MIR155 MEG3 MALAT1
41 myeloma, multiple 29.6 TUG1 PVT1 MEG3 MALAT1
42 nasopharyngeal carcinoma 29.5 PVT1 MEG3 MALAT1 CDKN2B-AS1
43 gallbladder cancer 29.4 TUG1 MEG3 MALAT1 CDKN2B-AS1
44 esophageal cancer 29.3 PVT1 MIR375 MIR30E MEG3 MALAT1 CDKN2B-AS1
45 lung cancer susceptibility 3 29.1 TUG1 MIR375 MEG3 MALAT1
46 lung squamous cell carcinoma 28.9 TUG1 PVT1 MIR375 MEG3
47 gastric cancer 28.9 TUG1 PVT1 MIR145 MEG3 MALAT1 CDKN2B-AS1
48 cervical cancer 28.9 TUG1 PVT1 MEG3 MALAT1 CDKN2B-AS1
49 glioma 28.8 PVT1 MIR17 MIR140 MEG3 MALAT1 CDKN2B-AS1
50 bladder cancer 28.8 TUG1 PVT1 MIR99A MIR145 MEG3 MALAT1

Graphical network of the top 20 diseases related to Diabetes Mellitus:



Diseases related to Diabetes Mellitus

Symptoms & Phenotypes for Diabetes Mellitus

UMLS symptoms related to Diabetes Mellitus:


tremor, angina pectoris, equilibration disorder, symptoms

Drugs & Therapeutics for Diabetes Mellitus

Drugs for Diabetes Mellitus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1039)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
3
Methyldopa Approved Phase 4 555-30-6 38853
4
Povidone Approved Phase 4 9003-39-8
5
Povidone-iodine Approved Phase 4 25655-41-8
6
Iodine Approved, Investigational Phase 4 7553-56-2 807
7
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
8
Succimer Approved Phase 4 304-55-2 9354
9
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
10
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
13
Nifedipine Approved Phase 4 21829-25-4 4485
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
15
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
16
Adalimumab Approved Phase 4 331731-18-1 16219006
17
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
18
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
19
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
20
Pramlintide Approved, Investigational Phase 4 151126-32-8
21
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
22
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
23
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
24
Gliquidone Approved, Investigational Phase 4 33342-05-1 91610
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Captopril Approved Phase 4 62571-86-2 44093
27
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
28
Tazobactam Approved Phase 4 89786-04-9 123630
29
Sultamicillin Approved, Investigational Phase 4 76497-13-7
30
Sulbactam Approved Phase 4 68373-14-8
31
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
32
Piperacillin Approved Phase 4 66258-76-2 43672
33
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
34
Fenofibrate Approved Phase 4 49562-28-9 3339
35
Magnesium oxide Approved Phase 4 1309-48-4 14792
36
leucovorin Approved Phase 4 58-05-9 143 6006
37
Bilberry Approved, Experimental Phase 4
38
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
39
Lacidipine Approved, Investigational Phase 4 103890-78-4
40
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
41
Enalaprilat Approved Phase 4 76420-72-9 6917719
42
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
43
Sodium citrate Approved, Investigational Phase 4 68-04-2
44
Trimetazidine Approved, Investigational Phase 4 5011-34-7
45
Lactulose Approved Phase 4 4618-18-2 11333
46
Citalopram Approved Phase 4 59729-33-8 2771
47
Eplerenone Approved Phase 4 107724-20-9 150310 443872
48
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
49
Hydroxychloroquine Approved Phase 4 118-42-3 3652
50
Ranibizumab Approved Phase 4 347396-82-1 459903

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
2 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
3 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
4 Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
5 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
6 A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists Unknown status NCT00144144 Phase 4 Angiotensin II receptor antagonists, Calcium channel blocker
7 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4 Repaglinide
8 A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
9 Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients Unknown status NCT01768208 Phase 4 Saxagliptin
10 Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study Unknown status NCT00427271 Phase 4 aspirin
11 A Randomized, Double-blind, Active Control, Parallel Group, Exploratory Phase IV Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin in Patients With Inadequately Controlled Type2 Diabetes Mellitus in Metformin Only Treatment Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
12 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
13 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4 Metformin;Metformin;Vildagliptin;Glimepiride
14 Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose? Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
15 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
16 A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response Unknown status NCT03027934 Phase 4 Ticagrelor;Prasugrel
17 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
18 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
19 Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
20 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
21 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
22 A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes Unknown status NCT00788840 Phase 4 Insulatard;Detemir
23 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
24 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
25 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
26 Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients Unknown status NCT01790308 Phase 4 CSII;Liraglutide
27 Phase IV Study of Antibacterial Effect on Silver Dressing of NPWT Unknown status NCT02274207 Phase 4
28 Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients. Unknown status NCT03123237 Phase 4
29 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
30 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus Unknown status NCT03120299 Phase 4 Omega-3 fatty acid;Placebos
31 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
32 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
33 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
34 A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
35 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
36 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
37 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
38 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
39 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
40 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
41 Effects of New Longacting Insulin Analogs on Metabolic Control, Endogenous Insulin Production, GH/IGF-I Axis and Quality of Life - Comparison of NPH, Glargine Och Detemir Insulin From the Debut of Type 1 Diabetes Mellitus in Adolescents Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
42 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
43 Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
44 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
45 An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
46 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
47 Efficacy of Combination of Glucometer and Mobile-phone Based Data Transfer System on Glycemic Control in Patients With Diabetes Unknown status NCT02769377 Phase 4
48 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
49 Effect of Reconstitute Multiple Grain on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Unknown status NCT00337337 Phase 4
50 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose

Search NIH Clinical Center for Diabetes Mellitus

Inferred drug relations via UMLS 72 / NDF-RT 51 :


CHROMIUM PICOLINATE
Insulin Aspart
Insulin Degludec
Insulin glargine
Insulin human
Insulin Lispro

Cochrane evidence based reviews: diabetes mellitus

Genetic Tests for Diabetes Mellitus

Genetic tests related to Diabetes Mellitus:

# Genetic test Affiliating Genes
1 Diabetes Mellitus 29

Anatomical Context for Diabetes Mellitus

MalaCards organs/tissues related to Diabetes Mellitus:

41
Heart, Kidney, Testes, Endothelial, Liver, Pancreas, Bone

Publications for Diabetes Mellitus

Articles related to Diabetes Mellitus:

(show top 50) (show all 52457)
# Title Authors PMID Year
1
Diabetes: Changing the conversation. 38 17
31124857 2019
2
Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015. 17
31124970 2019
3
Role of the physical fitness test in risk prediction of diabetes among municipal in-service personnel in Guangxi. 17
31145330 2019
4
Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. 9 38
19681913 2010
5
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. 9 38
20415560 2010
6
Plasma copeptin and the risk of diabetes mellitus. 9 38
20439785 2010
7
CTLA4 promoter polymorphisms are associated with canine diabetes mellitus. 9 38
20196832 2010
8
Comparative study of atherosclerotic parameters in Mongolian and Japanese patients with hypertension and diabetes mellitus. 9 38
20124737 2010
9
[A target of PPARgamma agonist: diabetes mellitus]. 9 38
20158098 2010
10
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity. 9 38
20143968 2010
11
Butyrylcholinesterase and diabetes mellitus in the CHE2 C5- and CHE2 C5+ phenotypes. 9 38
20414550 2010
12
[Metabolic syndrome, insulin resistance and cardiovascular disease in type-1 diabetes mellitus]. 9 38
20414537 2010
13
Acquired reactive perforating collagenosis in an insulin dependent diabetes mellitus patient. 9 38
20469788 2009
14
Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus. 9 38
19373836 2009
15
Motilin concentrations in relation to gastro intestinal dysmotility in diabetes mellitus. 9 38
19782932 2009
16
Cystatin C levels are unaltered in patients with diabetes mellitus and normal renal function. 9 38
19644487 2009
17
Haptoglobin genotype and endothelial function in diabetes mellitus: a pilot study. 9 38
19347351 2009
18
Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). 9 38
19329212 2009
19
[Diabetes susceptibility genes]. 9 38
19507498 2009
20
Aortic ER stress in streptozotocin-induced diabetes mellitus in APA hamsters. 9 38
19448334 2009
21
Overexpression of heme oxygenase-1 in coronary atherosclerosis of Japanese autopsies with diabetes mellitus: Hisayama study. 9 38
18620357 2009
22
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. 9 38
18949545 2009
23
No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. 9 38
18946177 2009
24
MicroRNA expression in human omental and subcutaneous adipose tissue. 88
19259271 2009
25
HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. 9 38
19252740 2009
26
Serum gamma-glutamyl transferase level and diabetes mellitus among US adults. 9 38
19449164 2009
27
Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus. 9 38
19060447 2008
28
WFS1 mutations are frequent monogenic causes of juvenile-onset diabetes mellitus in Lebanon. 9 38
18806274 2008
29
Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. 9 38
18706702 2008
30
Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. 9 38
18806525 2008
31
Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. 9 38
18514089 2008
32
Monocyte attachment and migration through collagen IV in diabetes mellitus. 9 38
18443419 2008
33
The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. 9 38
18317479 2008
34
Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. 9 38
18423055 2008
35
The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications. 9 38
18176722 2008
36
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. 9 38
18060660 2008
37
Activity of superoxide dismutase obtained from senile cataract lens - effect of diabetes mellitus. 9 38
19093039 2008
38
[Post-transplant diabetes mellitus depending on the pre-transplant dialysis technique]. 9 38
18957019 2008
39
Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. 9 38
18691043 2008
40
Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus. 9 38
18082523 2007
41
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. 9 38
18047925 2007
42
HNF4A genetic variants: role in diabetes. 9 38
17563455 2007
43
Evaluation of inhaled insulin therapy for diabetes mellitus. 9 38
17703168 2007
44
N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. 9 38
16397907 2007
45
Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. 9 38
17630927 2007
46
Insulin analogues: new dimension of management of diabetes mellitus. 9 38
17344794 2007
47
[Antihypertensive agents and the risk of new onset diabetes mellitus]. 9 38
17212194 2006
48
Estrogen receptors: new players in diabetes mellitus. 9 38
16890492 2006
49
[Aceruloplasminemia (hereditary ceruloplasmin deficiency) and diabetes mellitus]. 9 38
17022509 2006
50
[Calcium homeostasis and diabetes mellitus]. 9 38
16883034 2006

Variations for Diabetes Mellitus

ClinVar genetic disease variations for Diabetes Mellitus:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MEN1 NM_000244.3(MEN1): c.669+1delG deletion Pathogenic rs1057518903 11:64575362-64575362 11:64807890-64807890
2 KCNJ11 NM_000525.3(KCNJ11): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic rs80356625 11:17409038-17409038 11:17387491-17387491
3 KCNJ11 NM_000525.3(KCNJ11): c.964G> A (p.Glu322Lys) single nucleotide variant Pathogenic rs193929355 11:17408675-17408675 11:17387128-17387128
4 KCNJ11 NM_000525.3(KCNJ11): c.988T> C (p.Tyr330His) single nucleotide variant Pathogenic rs587783675 11:17408651-17408651 11:17387104-17387104
5 KCNJ11 NM_000525.3(KCNJ11): c.685G> A (p.Glu229Lys) single nucleotide variant Pathogenic rs587783673 11:17408954-17408954 11:17387407-17387407
6 KCNJ11 NM_000525.3(KCNJ11): c.679G> A (p.Glu227Lys) single nucleotide variant Pathogenic rs587783672 11:17408960-17408960 11:17387413-17387413
7 KCNJ11 NM_000525.3(KCNJ11): c.498C> G (p.Cys166Trp) single nucleotide variant Likely pathogenic rs587783669 11:17409141-17409141 11:17387594-17387594
8 ABCC8 NM_000352.5(ABCC8): c.1562G> A (p.Arg521Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs368114790 11:17464335-17464335 11:17442788-17442788
9 KCNJ11 NM_000525.3(KCNJ11): c.463G> A (p.Val155Met) single nucleotide variant Uncertain significance rs587783668 11:17409176-17409176 11:17387629-17387629
10 CEL NM_001807.5(CEL): c.1966G> C (p.Ala656Pro) single nucleotide variant Uncertain significance rs587780309 9:135946855-135946855 9:133071468-133071468

Copy number variations for Diabetes Mellitus from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 110220 17 3154257 3410803 Deletion HNF1b Diabetes mellitus
2 110369 17 31923035 33323544 Deletion HNF1B Diabetes mellitus
3 110541 17 33120546 33179209 Deletion HNF1B Diabetes mellitus
4 203632 1 158846514 158883705 Rearrangement SLAM Diabetes mellitus
5 225144 7 43300000 45400000 Gain or loss GCK Diabetes mellitus

Expression for Diabetes Mellitus

Search GEO for disease gene expression data for Diabetes Mellitus.

Pathways for Diabetes Mellitus

Pathways related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 MIR99A MIR375 MIR30E MIR17 MIR155 MIR145
2
Show member pathways
11.42 KCNJ11 INS ABCC8
3 11.18 MIR375 MIR30E MIR17 MIR132
4 10.98 KCNJ11 INS ABCC8

GO Terms for Diabetes Mellitus

Cellular components related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155
2 inward rectifying potassium channel GO:0008282 8.96 KCNJ11 ABCC8

Biological processes related to Diabetes Mellitus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.63 MIR17 MIR140 MALAT1
2 negative regulation of gene expression GO:0010629 9.62 MIR17 MIR155 MIR132 CDKN2B-AS1
3 negative regulation of vascular endothelial cell proliferation GO:1905563 9.49 MIR30E MIR132
4 positive regulation of endothelial cell apoptotic process GO:2000353 9.48 MIR375 MIR132
5 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.43 MIR155 ABCC8
6 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.4 MIR17 MIR155
7 fatty acid homeostasis GO:0055089 9.37 MIR132 INS
8 gene silencing by miRNA GO:0035195 9.36 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155
9 miRNA mediated inhibition of translation GO:0035278 9.35 MIR17 MIR155 MIR145 MIR134 MIR132
10 negative regulation of sprouting angiogenesis GO:1903671 9.33 MIR375 MIR30E MIR17
11 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.26 MIR17 MIR155

Molecular functions related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR30E MIR17 MIR155 MIR145 MIR140 MIR134
2 RNA polymerase II complex binding GO:0000993 9.13 MIR375 MIR145 MIR140
3 ATP-activated inward rectifier potassium channel activity GO:0015272 8.85 KCNJ11

Sources for Diabetes Mellitus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....